Landos Biopharma, Inc. (LABP)
$4.26
Rating:
Recommendation:
-
| Symbol | LABP |
|---|---|
| Price | $4.26 |
| Beta | -0.551 |
| Volume Avg. | 0.01M |
| Market Cap | 13.277M |
| Shares () | - |
| 52 Week Range | 2.2-6.2 |
| 1y Target Est | - |
| DCF Unlevered | LABP DCF -> | |
|---|---|---|
| DCF Levered | LABP LDCF -> | |
| ROE | -46.09% | Strong Sell |
| ROA | -44.53% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -1.11 | Sell |
| P/B | 0.70 | Buy |
Latest LABP news
About
Download (Excel)Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.